Worth reading
45Recurring
Scored from 4 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
89.2
%Wording
Conditional
How definitive the wording is.Results for this period
Third quarter2024年4月1日〜2024年12月31日ConsolidatedJapanese GAAPNet Sales41,238¥ millionYear on year +1.9%
Operating profit2,903¥ millionYear on year +89.2%
Ordinary income3,347¥ millionYear on year +83.1%
Net income attributable to owners of the parent2,113¥ millionYear on year +83.0%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit.
Financial position at period-end
Total assets86,068¥ million
of which net assets 58,808 ¥ million
The shaded area represents net assets as a proportion of total assets. It is calculated from the two amounts reported by the company.
Segment revenueFunctional Materials Business ¥21,788 million (YoY +2.6%), Electronic materials and chemicals business ¥18,607 million (YoY +1.6%), Other ¥841 million (YoY -9.1%)
Segment profitFunctional Materials Business ¥1,291 million, Electronic materials and chemicals business ¥1,434 million, Other ¥179 million
Outlook and shareholder returns
Revision to Earnings ForecastNet Sales No change / Operating profit No change / Ordinary income No change / Net income No change
Factors Behind Changes in Business Performance
化粧品向け微粒子酸化チタン等の販売が好調であったこと、車載用コンデンサ向けを中心に導電性高分子薬剤の販売も好調に推移したこと等
Disclosure regarding the going concern assumption
No applicable matters
Change in accounting policy
基準改正に伴う変更 Yesそれ以外の変更 No見積りの変更 No修正再表示 No
Impairment lossNo applicable matters
Breakdown of extraordinary income (loss)Loss on Disposal of Fixed Assets ¥227 million
Depreciation and amortization¥2,023 million
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2024年4月1日〜2024年12月31日 |
| Net Sales | ¥41,238 million (YoY +1.9%) |
| Operating profit | ¥2,903 million (YoY +89.2%) |
| Ordinary income | ¥3,347 million (YoY +83.1%) |
| Profit attributable to owners of the parent | ¥2,113 million (YoY +83.0%) |
| Total assets | ¥86,068 million |
| Net assets | ¥58,808 million |
| Revision to Earnings Forecast | Net Sales No change / Operating profit No change / Ordinary income No change / Net income No change |
| Segment revenue | Functional Materials Business ¥21,788 million (YoY +2.6%), Electronic materials and chemicals business ¥18,607 million (YoY +1.6%), Other ¥841 million (YoY -9.1%) |
| Segment profit | Functional Materials Business ¥1,291 million, Electronic materials and chemicals business ¥1,434 million, Other ¥179 million |
| Depreciation and amortization | ¥2,023 million |
| Impairment loss | No applicable matters |
| Breakdown of extraordinary income (loss) | Loss on Disposal of Fixed Assets ¥227 million |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards Yes / Other changes No / Change in accounting estimate No / Restatement No |
| Factors Behind Changes in Business Performance | 化粧品向け微粒子酸化チタン等の販売が好調であったこと、車載用コンデンサ向けを中心に導電性高分子薬剤の販売も好調に推移したこと等 |
Items this document does not state (19)
Net income per shareOperating MarginEquity ratioCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodFull-year earnings forecastAnnual Dividend ForecastPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogChanges in the scope of consolidationMaterial subsequent eventsAvailability of Supplementary Financial Results MaterialsAvailability of Financial Results BriefingIssued Shares at Period-EndTreasury Shares at Period-End
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.化粧品向け微粒子酸化チタン等の販売が好調だったこと、車載用コンデンサ向けを中心に導電性高分子薬剤の販売も好調に推移したこと等。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.